GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » EBIT

Biora Therapeutics (Biora Therapeutics) EBIT : $-101.23 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics EBIT?

Biora Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-1.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-101.23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biora Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -122.43%. Biora Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -207.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biora Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -176.86%.


Biora Therapeutics EBIT Historical Data

The historical data trend for Biora Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics EBIT Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -140.12 -107.62 -166.00 -38.26 -114.61

Biora Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.76 -15.10 -70.86 -13.89 -1.38

Competitive Comparison of Biora Therapeutics's EBIT

For the Biotechnology subindustry, Biora Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biora Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's EV-to-EBIT falls into.



Biora Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-101.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biora Therapeutics  (NAS:BIOR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biora Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-62.064 * ( 1 - -1.16% )/( (59.979 + 42.582)/ 2 )
=-62.7839424/51.2805
=-122.43 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Biora Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.536/( ( (2.77 + max(-57.07, 0)) + (2.554 + max(-45.779, 0)) )/ 2 )
=-5.536/( ( 2.77 + 2.554 )/ 2 )
=-5.536/2.662
=-207.96 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.03) - (15.137 + 0.542 + 44.421)
=-57.07

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.429) - (17.441 + 0 + 30.767)
=-45.779

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biora Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-101.232/57.238
=-176.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biora Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biora Therapeutics (Biora Therapeutics) Business Description

Traded in Other Exchanges
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.
Executives
Athyrium Opportunities Iii Co-invest 1 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty director, officer: Chief Executive Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe director C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp 10 percent owner 605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi officer: Chief Compliance Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry officer: Chief Operating Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter director 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp 10 percent owner 505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli director, officer: Chairman & CEO 3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper officer: Chief Scientific Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104